Subscribe To
FMS / Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top
FMS News
By Zacks Investment Research
November 3, 2023
Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue t more_horizontal
By Seeking Alpha
November 2, 2023
Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript more_horizontal
By Zacks Investment Research
October 23, 2023
Top Medical Stocks to Buy Amid Recent Market Volatility
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for inv more_horizontal
By Zacks Investment Research
October 16, 2023
Here's Why You Should Retain Fresenius Medical (FMS) for Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe. more_horizontal
By Reuters
October 12, 2023
Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers
Germany's Fresenius Medical Care , said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral more_horizontal
By The Motley Fool
October 11, 2023
Why Shares of Fresenius Medical Care Were Dropping on Wednesday
Novo Nordisk ended a phase 3 trial early for Ozempic for preventing kidney disease because the trial was so successful. Fresenius and other dialysis-c more_horizontal
By Market Watch
October 11, 2023
Dialysis company shares plunge after Ozempic trial success vs. kidney trouble
The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday. more_horizontal
By Zacks Investment Research
September 15, 2023
Here's Why You Should Retain Fresenius Medical (FMS) for Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe. more_horizontal